GRIN Therapeutics, Inc.
PrivateLast Round
Series D
May 28, 2025
Total Funding Raised
$140M
Company Overview
GRIN Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops precision therapies for pediatric neurodevelopmental disorders. The company's primary focus is on its lead investigational drug, radiprodil, a negative allosteric modulator that selectively targets the GluN2B subunit of the NMDA receptor. This drug is being developed to treat GRIN-related neurodevelopmental disorder (GRIN-NDD), as well as other conditions like tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD). Founded in 2021, the company is an affiliate of Neurvati Neurosciences and a portfolio company of Blackstone Life Sciences. GRIN Therapeutics has received significant funding, including a $140 million Series D financing in May 2025, to advance radiprodil into a global Phase 3 clinical trial. The company has also entered a strategic collaboration with Angelini Pharma for the commercialization of radiprodil outside of North America.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GRIN Therapeutics, Inc. Comparables
Compare GRIN Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Noema Pharma | 76% | |
| Actio Biosciences | 73% | |
| Stoke Therapeutics, Inc. | 69% |
GRIN Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | May 28, 2025 |
GRIN Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Blackstone Life Sciences | Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 98% MoM, reaching 2.1K.
- Dec 11, 2025
Partnered with InformedDNA to offer free genetic counseling to US patients.
GRIN Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access